Pharmacogenomics of Antifungal Agents

A-40; 2004. [79] Arredondo G, Calvo R, Marcos F, Martinez-Jorda R, Suarez E. Protein binding of itraconazole and fluconazole in patients with cancer. Int J Clin Pharmacol Ther 1995;33(8):449–52. [80] Brajtburg J, Elberg S, Bolard J, Kobayashi GS, Levy RA, Ostlund Jr RE. Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis 1984;149(6):986–97. [81] Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002;46(3):834–40. [82] Kragh-Hansen U, Minchiotti L, Galliano M, Peters Jr T. Human serum albumin isoforms: genetic and molecular aspects and functional consequences. Biochim Biophys Acta 2013;1830(8):5405–17. 899 Chapter | 38 Pharmacogenomics of Antifungal Agents [83] Nishi K, Ueno M, Murakami Y, Fukunaga N, Akuta T, Kadowaki D. A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human alpha(1)-acid glycoprotein. J Pharm Sci 2009;98(11):4316–26. [84] Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78(3):260–77. [85] Valeriote F, Medoff G, Dieckman J. Potentiation of anticancer agent cytotoxicity against sensitive and resistant AKR leukemia by amphotericin B1. Cancer Res 1979;39(6 Pt 1):2041–5. [86] Ishizaki J, Ito S, Jin M, Shimada T, Ishigaki T, Harasawa Y. Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B. Biopharm Drug Dispos 2008;29(4):195–203. [87] Miyama T, Takanaga H, Matsuo H, Yamano K, Yamamoto K, Iga T. P-glycoprotein-mediated transport of itraconazole across the bloodbrain barrier. Antimicrob Agents Chemother 1998;42(7):1738–44. [88] Imbert F, Jardin M, Fernandez C, Gantier JC, Dromer F, Baron G. Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans. Drug Metab Dispos 2003;31(3):319–25. [89] Yoshikado T, Takada T, Yamamoto T, Yamaji H, Ito K, Santa T. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol 2011;79(2):241–50. [90] Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42(13):1141–60. [91] Uno T, Shimizu M, Sugawara K, Tateishi T. Lack of dosedependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos 2006;34(11):1875–9. [92] Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006;34(7):1229–36. [93] Yamaguchi H, Takeuchi T, Okada M, Kobayashi M, Unno M, Abe T. Screening of antibiotics that interact with organic aniontransporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull 2011;34(3):389–95. [94] Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37(5):728–32. [95] Weiler S, Fiegl D, MacFarland R, Stienecke E, Bellmann-Weiler R, Dunzendorfer S. Human tissue distribution of voriconazole. Antimicrob Agents Chemother 2011;55(2):925–8. [96] Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet 2010;49(6):379–96. [97] Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother